| (Values in U.S. Thousands) | Jun, 2021 | Mar, 2021 | Dec, 2020 | Sep, 2020 | Jun, 2020 |
| Sales | 19,690 | 18,350 | 18,260 | 17,740 | 13,710 |
| Sales Growth | +7.30% | +0.49% | +2.93% | +29.39% | -23.41% |
| Net Income | -4,470 | -3,760 | -1,270 | -4,980 | -8,540 |
| Net Income Growth | -18.88% | -196.06% | +74.50% | +41.69% | -52.77% |
Misonix Inc (MSON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Misonix, Inc. designs, develops, manufactures, and markets medical, scientific, and industrial ultrasonic equipment, laboratory safety equipment, and air pollution control products. Misonix's ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc. which uses high intensity focused ultrasound technology to destroy deep-seated cancerous tissues without affecting surrounding healthy tissue. Misonix acquired worldwide rights to use the Focus technology in kidney, liver and breast treatment. Addressing a combined market estimated to be in excess of $four billion annually, Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.
Fiscal Year End Date: 06/30